<DOC>
	<DOCNO>NCT02536859</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare pharmacodynamic ( effect investigate drug body ) pharmacokinetic ( exposure trial drug body ) property insulin degludec insulin glargine 300 U/mL steady-state condition subject type 1 diabetes mellitus .</brief_summary>
	<brief_title>Comparing Pharmacodynamic Pharmacokinetic Properties Insulin Degludec Insulin Glargine 300 U/mL Steady-state Conditions Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female age 1864 year ( inclusive ) time sign informed consent Subjects diagnose ( clinically ) type 1 diabetes mellitus least 365 day prior day screen Body mass index 18.529.0 kg/m^2 ( inclusive ) Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoke 5 cigarette equivalent per day ) able willing refrain smoking use nicotine gum transdermal nicotine patch inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>